New Insights in Gastric, Colorectal, and Pancreatic Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 114
Special Issue Editor
Interests: nutrition; inflammatory bowel disease; malabsorption syndromes; chronic diarrhea; small and large bowel disorders; cancer epidemiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Gastric, colorectal and pancreatic cancer represent the most important malignant neoplasms of the digestive system in terms of frequency and clinical importance. Despite the apparent changes regarding their frequency, it seems that these neoplasms are appearing at younger ages. Over the last years, significant progress has been made in the etiology, diagnosis and therapeutic treatment (surgical and conservative) of these three malignant neoplasms, including their pre-cancerous conditions (polyps, IBD, etc.). Advances in conservative treatment are especially impressive. For example, immunotherapy of these cancers alone or in combination with systemic chemotherapy is the therapeutic strategy of the present and the future.
This Special Issue focuses on the recent data regarding these three neoplasms, intending to cover among others, the following topics:
- Mechanisms of carcinogenesis;
- Tumor cell biology;
- Hereditary gastric, CRC and pancreatic cancer;
- Polyps (gastric and colorectal);
- Biomarkers (diagnostic and prognostic);
- Tumor staging;
- Imaging techniques;
- Animal models;
- Stem cells;
- Advances in chemotherapy;
- Immunotherapy in gastric and pancreatic cancer, alone or in combination;
- Advances in the treatment of metastatic pancreatic, CRC and gastric cancer.
We aspire for this Special Issue to cover at least part of the wide spectrum of the etiologies, diagnoses and treatments of these neoplasms, always in the light of a multidisciplinary approach.
Dr. John K. Triantafillidis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gastric cancer
- colorectal cancer
- pancreatic cancer
- immunotherapy
